Biophytis (EPA:ALBPS)

REGULATED PRESS RELEASE

published on 04/24/2024 at 23:00, 1 year 9 months ago

Biophytis Announces Transfer of ADSs to OTC Market
Biophytis announces the transfer of ADSs from Nasdaq to OTC Market, resulting in cost savings. Company to trade on OTCQB while remaining listed on Euronext Growth Paris

Euronext Growth Paris Biophytis Nasdaq OTC Market ADSs
BRIEF

published on 04/19/2024 at 07:05, 1 year 9 months ago

Biophytis Announces Significant Change in ADR Program Ratio

Biophytis Biotechnology Nasdaq ADR Program Stock Ratio Change
PRESS RELEASE

published on 04/19/2024 at 07:00, 1 year 9 months ago

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
Biophytis announces ratio change for its American Depositary Receipt (ADR) program, with effective date expected to be April 23, 2024

Biophytis Stock Market American Depositary Receipt ADR Program Ratio Change
REGULATED PRESS RELEASE

published on 04/19/2024 at 07:00, 1 year 9 months ago

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
Biophytis announces ratio change for its American Depositary Receipt program, affecting ADS to Shares ratio. No new shares issued, trading price may increase. Details provided in the press release

Biophytis Shares Ads American Depositary Receipt Ratio Change
BRIEF

published on 04/18/2024 at 07:05, 1 year 9 months ago

Biophytis Announces New Scientific Advisory Board for Phase 2 Obesity Study

Biophytis Scientific Advisory Board BIO101 Obesity OBA Clinical Study
PRESS RELEASE

published on 04/18/2024 at 07:02, 1 year 9 months ago

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Biophytis appoints new Scientific Advisory Board for phase 2 OBA clinical study in obesity with Prof. Dennis Villareal and Prof. Francisco Guarner. IND filing with FDA soon

FDA Biophytis Scientific Advisory Board Obesity OBA Clinical Study
REGULATED PRESS RELEASE

published on 04/18/2024 at 07:00, 1 year 9 months ago

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Biophytis forms new Scientific Advisory Board for phase 2 OBA clinical study in obesity, including Professor Dennis Villareal and Professor Francisco Guarner. IND filing with FDA imminent

Biophytis Scientific Advisory Board Obesity Phase 2 OBA Clinical Study IND Filing
BRIEF

published on 04/15/2024 at 07:05, 1 year 9 months ago

Biophytis Enhances Intellectual Property in Obesity Treatment with New Patent Application

Biophytis Pharmaceuticals Patent Application BIO101 Obesity
REGULATED PRESS RELEASE

published on 04/15/2024 at 07:00, 1 year 9 months ago

Biophytis files a patent application and strengthens its intellectual property in obesity
Biophytis files a patent application to strengthen its intellectual property in obesity. The new patent extends BIO101's exclusivity period in treating obesity, positioning Biophytis in a fast-growing market

Biophytis Intellectual Property Clinical Trial Patent Application Obesity
BRIEF

published on 04/08/2024 at 23:17, 1 year 9 months ago

Biophytis Reports 2023 Financial Results and Business Updates

Biophytis Financial Results 2023 Sarcopenia BIO101 COVID-19 Treatment

Published on 01/31/2026 at 03:15, 4 hours 17 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 5 hours 12 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 5 hours 52 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 7 hours 32 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 8 hours 32 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 4 hours 46 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 9 hours 32 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 11 hours 21 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 11 hours 22 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 11 hours 24 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 13 hours 47 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 23 hours 32 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 13 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 13 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 13 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News